ClinicalTrials.gg

Program

HRS-3095

A development code. Also written as “HRS-3095 Tablet”.

Its studies are mostly in Chronic Urticaria, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since May 22, 20263 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine32 open or runningphase 2since May 22, 2026Nov 13, 2025Dec 2026phase 2 · NCT07613866
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-3095, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2025First study: phase 1 study in Chronic UrticariaFirst studyNCT07230418 · 82 enrolled · China
  2. May 22, 2026Phase 2 study in Chronic UrticariaPhase 2 reachedNCT07613866 · 190 planned · China
  3. Jun 22, 2026Early phase 1 study in Chronic UrticariaNCT07686484 · 36 enrolled · Australia

Ahead

  1. Dec 2026Primary completion: phase 2 study in Chronic UrticariaNCT07613866

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07686484Chronic Urticaria · AustraliaEarly 1Active, not recruitingOct 16, 202636
NCT07613866Chronic Urticaria · China2Not yet recruitingDec 2026190
NCT07230418Chronic Urticaria · China1CompletedApr 19, 202682

How it is read

Names in the registry

  • “HRS-3095”, 3 entries
  • “HRS-3095 Tablet”, 2 entries

Codes read as this program: HRS3095.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.